Show simple item record

dc.contributor.authorPanek, R
dc.contributor.authorWelsh, L
dc.contributor.authorDunlop, A
dc.contributor.authorWong, KH
dc.contributor.authorRiddell, AM
dc.contributor.authorKoh, D-M
dc.contributor.authorSchmidt, MA
dc.contributor.authorDoran, S
dc.contributor.authorMcquaid, D
dc.contributor.authorHopkinson, G
dc.contributor.authorRichardson, C
dc.contributor.authorNutting, CM
dc.contributor.authorBhide, SA
dc.contributor.authorHarrington, KJ
dc.contributor.authorRobinson, SP
dc.contributor.authorNewbold, KL
dc.contributor.authorLeach, MO
dc.date.accessioned2020-06-22T15:47:20Z
dc.date.issued2016-07-01
dc.identifier.citationJournal of magnetic resonance imaging : JMRI, 2016, 44 (1), pp. 72 - 80
dc.identifier.issn1053-1807
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3763
dc.identifier.eissn1522-2586
dc.identifier.doi10.1002/jmri.25134
dc.description.abstractPURPOSE: To determine whether quantitation of T2* is sufficiently repeatable and sensitive to detect clinically relevant oxygenation levels in head and neck squamous cell carcinoma (HNSCC) at 3T. MATERIALS AND METHODS: Ten patients with newly diagnosed locally advanced HNSCC underwent two magnetic resonance imaging (MRI) scans between 24 and 168 hours apart prior to chemoradiotherapy treatment. A multiple gradient echo sequence was used to calculate T2* maps. A quadratic function was used to model the blood transverse relaxation rate as a function of blood oxygenation. A set of published coefficients measured at 3T were incorporated to account for tissue hematocrit levels and used to plot the dependence of fractional blood oxygenation (Y) on T2* values, together with the corresponding repeatability range. Repeatability of T2* using Bland-Altman analysis, and calculation of limits of agreement (LoA), was used to assess the sensitivity, defined as the minimum difference in fractional blood oxygenation that can be confidently detected. RESULTS: T2* LoA for 22 outlined tumor volumes were 13%. The T2* dependence of fractional blood oxygenation increases monotonically, resulting in increasing sensitivity of the method with increasing blood oxygenation. For fractional blood oxygenation values above 0.11, changes in T2* were sufficient to detect differences in blood oxygenation greater than 10% (Δ T2* > LoA for ΔY > 0.1). CONCLUSION: Quantitation of T2* at 3T can detect clinically relevant changes in tumor oxygenation within a wide range of blood volumes and oxygen tensions, including levels reported in HNSCC. J. Magn. Reson. Imaging 2016;44:72-80.
dc.formatPrint-Electronic
dc.format.extent72 - 80
dc.languageeng
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectCarcinoma, Squamous Cell
dc.subjectHead and Neck Neoplasms
dc.subjectOxygen
dc.subjectImage Interpretation, Computer-Assisted
dc.subjectObserver Variation
dc.subjectMagnetic Resonance Imaging
dc.subjectSensitivity and Specificity
dc.subjectReproducibility of Results
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectBiomarkers, Tumor
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titleRepeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T.
dc.typeJournal Article
dcterms.dateAccepted2015-12-02
rioxxterms.versionofrecord10.1002/jmri.25134
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of magnetic resonance imaging : JMRI
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Pre-Clinical MRI
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume44
pubs.embargo.termsNot known
icr.researchteamMagnetic Resonance
icr.researchteamPre-Clinical MRI
icr.researchteamTargeted Therapy
dc.contributor.icrauthorDoran, Simon
dc.contributor.icrauthorHarrington, Kevin
dc.contributor.icrauthorRobinson, Simon
dc.contributor.icrauthorLeach, Martin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0